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Although Th17 cells are known to promote tissue
inflammation and autoimmunity, their role during
cancer progression remains elusive. Here, we
showed that in vitro Th17 cells generated with the
cytokines IL-6 and TGF-b expressed CD39 and
CD73 ectonucleotidases, leading to adenosine
release and the subsequent suppression of CD4+
and CD8+ T cell effector functions. The IL-6-medi-
ated activation of the transcription factor Stat3 and
the TGF-b-driven downregulation of Gfi-1 transcrip-
tion factor were both essential for the expression of
ectonucleotidases during Th17 cell differentiation.
Stat3 supported whereas Gfi-1 repressed CD39 and
CD73 expression by binding to their promoters.
Accordingly, Th17 cells differentiated with IL-1b,
IL-6, and IL-23 but without TGF-b did not express
ectonucleotidases and were not immunosuppres-
sive. Finally, adoptive transfer of Th17 cells induced
by TGF-b and IL-6 promoted tumor growth in a
CD39-dependent manner. Thus, ectonucleotidase
expression supports the immunosuppressive fate
of Th17 cells in cancer.
INTRODUCTION
CD4+ T helper (Th) lymphocytes are main regulators of adaptive
immune responses. Upon recognition of their cognate antigen in
the context of associated environmental signals, naive CD4+362 Immunity 36, 362–373, March 23, 2012 ª2012 Elsevier Inc.T cells differentiate into Th1, Th2, Th17, and regulatory T (Treg)
cells that are characterized by the expression of their respective
transcription factors T-bet (Szabo et al., 2000), Gata-3 (Zheng
and Flavell, 1997), Rorgt (Ivanov et al., 2006), and Foxp3 (Fonte-
not et al., 2003). Although these various T cell subsets orches-
trate the host defense responses against pathogens, they have
been shown to contribute to immunopathology in autoimmune
diseases and cancers (Korn et al., 2009; Yamaguchi and Saka-
guchi, 2006; Zou and Restifo, 2010).
In addition to IL-17a and IL-17f, Th17 cells are characterized
by their secretion of IL-21 and IL-22 and their expression of the
IL-23 receptor (IL-23R) (Yamaguchi and Sakaguchi, 2006).
Th17 cell development is selectively induced by a combination
of IL-6 and TGF-b, and the IL-12 family member IL-23 maintains
Th17 cell activity (Chen and O’Shea, 2008). Th17 cells have
emerged as key participants in a wide range of autoimmune
disorders, including inflammatory bowel disease, psoriasis,
and ankylosing spondylitis (van den Berg and Miossec, 2009).
IL-17 contributes to inflammation through many mechanisms,
including the population expansion and recruitment of myeloid
cells. Along with the Th17 cell-associated cytokine IL-21, IL-17
provides help to B cells (Mitsdoerffer et al., 2010).
Th17 cell populations are limited in healthy mice, but relatively
expanded in the blood-, bone marrow-, and spleen tumor-
bearing mice. Th17 cell expansion was also observed in human
cancers such as melanoma, prostate cancer, fibrosarcoma,
and advanced head and neck cancer (Miyahara et al., 2008;
Sfanos et al., 2008; Su et al., 2010). Despite these early observa-
tions, the role of Th17 cells in cancer immunity remains contro-
versial. IL-17 has been shown to promote angiogenesis and
inflammation through Stat3 signaling and myeloid-derived
suppressor cell (MDSC) mobilization (He et al., 2010; Wang
et al., 2009), resulting in tumor progression. However, adoptive
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Figure 1. Th17 Cells Induced by TGF-b and
IL-6 Express Ectonucleotidases
(A) RNA isolated from naive CD4+CD62Lhi cells
differentiated with or without cytokines into Th0,
Th1, Th2, Treg, or Th17 cells in the presence of
anti-CD3 and anti-CD28 was subjected to quanti-
tative real-time PCR (RT-PCR) relative to the
expression of mRNA encoding cyclophilin to
examine expression of Entpd1 (left) and Nt5e
(right) at 72 hr after activation.
(B) Flow cytometry analysis of CD39 and CD73
expression at 96 hr in Th1, Th2, Treg, and Th17
cells.
(C) The diphosphohydrolase activity of naive
CD4+CD62Lhi cells differentiated with or without
cytokines into Th1, Th2, Treg, or Th17 cells in the
presence of anti-CD3 and anti-CD28 is depicted.
(D) Hydrolysis of extracellular 14C-radiolabeled
ADP to adenosine in Th1, Th2, Treg, and Th17
cells.
(E) Naive CD4+ T cells from Rorgt reporter mice
were differentiated into Th17 cells for 72 hr and the
expression of CD39 and CD73 on Rorgt-express-
ing cells was assessed by flow cytometry.
Representative data from one of three experiments
are shown. For multiple groups, comparison the
Kruskal-Wallis statistics test followed by Dunn’s
post test was used (A, C, D). Graphs show mean ±
SEM, *p < 0.05.
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Ectonucleotidase Expression by Th17 Cellstransfer of tumor-specific Th17 cells could control tumor
growth as a result of their capacity to promote cytotoxic T cell
activation (Martin-Orozco et al., 2009; Muranski et al., 2008).
Although the molecular bases for these discrepancies are
elusive, these studies suggest that Th17 cells may exert regula-
tory or inflammatory functions depending on the cytokine
microenvironment.
Here, we found that in vitro Th17 cells generated with IL-6 and
TGF-b express CD39 and CD73 ectonucleotidases, leading to
adenosine release and the suppression of effector T cells. The
expression of ectonucleotidases was dependent on IL-6-driven
Stat3 activation and TGF-b-mediated downregulation of zinc
finger protein growth factor independent-1 (Gfi-1) that both tran-
scriptionally regulate ectonucleotidases expression during Th17
cell differentiation. Finally, CD39 expression on Th17 cells
promoted tumor growth, suggesting that expression of ectonu-Immunity 36, 362–37cleotidases dictates the immunosuppres-
sive fate of Th17 cells in cancer.
RESULTS
Th17 Cells Induced by TGF-b
and IL-6ExpressEctonucleotidases
The expression of CD39 and CD73 ecto-
nucleotidases on Foxp3+ Treg cells leads
to the release of adenosine, resulting in
immune suppression (Deaglio et al.,
2007). The concomitant expression of
these two enzymes that catalyzes the
transformation of extracellular ATP or
ADP into adenosine dampens T cellresponses (Deaglio et al., 2007). We analyzed the expression
of CD39 and CD73 on naive CD4+ T cells differentiated into
Th0, Th1, Th2, Treg, or Th17 cells. Both quantitative PCR and
flow cytometry analysis showed that only Th17 and Treg cells
expressed both CD39 (encoded by Entpd1) and CD73 (encoded
by Nt5e) (Figures 1A and 1B). We then tested the functionality of
the ectonucleotidases expressed on Th17 cells. Th17 cells had
a nucleoside triphosphate diphosphohydrolase activity compa-
rable to Treg cells (Figure 1C). Additionally, whereas Th17 cells
were able to transform ADP into adenosine, Th1 and Th2 cells
were unable to produce the immunosuppressive molecule
adenosine (Figure 1D and Figure S1A available online). To test
whether ectonucleotidase expression was restricted to bona
fide Th17 cells that express Rorgt, we used Rorgt-EGFP mice.
Upon differentiation of naive T cells from these mice with
TGF-b and IL-6, we observed that the concomitant expression3, March 23, 2012 ª2012 Elsevier Inc. 363
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Figure 2. Th17 Cells Suppress Effector T
Cell Activation
(A) 105 cell-sorted purified TCR transgenic CD8+
OT-I cells together with the OVA-derived SIINFEKL
peptide were subsequently cocultured with
increasing dosage of Th17 or Treg cells (at a 1:1
ratio). Th17 cells were generated from purified
naive T cells stimulated with CD3 and CD28 anti-
bodies with TGF-b and IL-6 and for 72 hr. IFN-g
levels were then assessed by ELISA.
(B) Naive CD4+ T cells from Rorgt reporter mice
were differentiated into Th17 cells for 72 hr, cell
sorted based on their Rorgt expression, and
cocultured with OT-I cells as in (A). The IFN-g
secretion from OT-I cells after 72 hr was analyzed
by intracellular staining.
(C) Th17 or Treg cells were generated and
cocultured with OT-I cells as in (A) for 72 hr.
Granzyme B expression levels were assessed by
flow cytometry.
(D) MCA205OVA fibrosarcoma cells were cocul-
tured for 24 hr with OT-I cells in the presence
or absence of Th17 cells from Entpd1+/+ and
Entpd1/ hosts. Tumor cell death was evaluated
by Annexin V/propidium iodide staining.
(E) Th17 cells from Entpd1+/+ and Entpd1/ hosts
were differentiated into Th17 cells and cocultured
with OT-I cells as in (A) (left); Th17 cells were
cultured with OT-I cells as in (A) in the presence of
a2a or a2b inhibitors (right).
(F) OT-II cells were cocultured as in (A) with Th17 or
Treg cells. IFN-g and IL-2 concentrations in the
coculture were measured by ELISA.
Representative data from one of three (A, C–F)
or one of two (E) experiments are shown. For
multiple groups comparison, the Kruskal-Wallis
statistics test followed by Dunn’s post test was
used (A, C–F). Graphs show mean ± SEM,
*p < 0.05.
Immunity
Ectonucleotidase Expression by Th17 Cellsof both CD39 and CD73 was restricted to GFP+ cells (Figure 1E).
As reported previously (Bettelli et al., 2006), Foxp3 was not
expressed in Rorgt-EGFP cells polarized into Th17 cells either
in the GFP-positive or GFP-negative fraction, which further indi-
cated that the expression of ectonucleotidases in GFP+ cells was
due solely to Th17 cells and not to Treg cells (Figure S1B).
Thus, Th17 cells generated with TGF-b and IL-6 possess ecto-
nucleotidase catalytic machinery, suggesting that they might
contribute to immune regulation.
CD39+CD73+ Th17 Cells Impair Effector T Cell
Responses
Adenosine inhibits a series of T cell effector functions such as
interleukin-2 (IL-2) and interferon-g (IFN-g) secretion and the364 Immunity 36, 362–373, March 23, 2012 ª2012 Elsevier Inc.release of cytolytic effector molecules
(Duhant et al., 2002). Because ectonu-
cleotidases were highly expressed in
Th17 cells, we tested their immunosup-
pressive activity on effector CD4+ and
CD8+ T cells. Th17 cells could blunt
IFN-g production from activated OT-I
CD8+Tcells in adose-dependentmanner.Th17 cells exerted comparable suppressive activity as Treg cells
(Figure 2A). Because Th17 cells have been described to secrete
IFN-g upon restimulation (Harrington et al., 2005), we tested
the suppressive capacity of Th17 cells derived from Ifng/
mice. Ifng/ Th17 cells were as suppressive as wild-type
Th17 cells, excluding a contribution of IFN-g production from
Th17 cells in our observations (Figure S2A). CD39 enzyme
cleaves ATP or ADP into AMP. CD73, however, is required
to convert AMP into the final immunosuppressive molecule
adenosine. Thus, both molecules are required to produce aden-
osine. Whereas Th17 cells were able to transform ADP into
adenosine, Th1 cells could convert ADP only into AMP and
failed to produce the immunosuppressive molecule adenosine
(Figure 1D). Accordingly, Th1 cells, which expressed CD39 but
Immunity
Ectonucleotidase Expression by Th17 Cellsnot CD73, did not affect IFN-g production from OT-I cells
(Figure S2A).
Similar results were obtainedwith GFP+CD4+ cells fromRorgt-
EGFP mice differentiated into Th17 cells, thus confirming that
CD39+CD73+ Th17 cells have an immunosuppressive effect (Fig-
ure 2B). Th17 cells also negatively regulate CD8+ T cell cytotoxic
properties. Indeed, they could downregulate granzyme B
expression from activated OT-I cells and were able to blunt
OT-I cytotoxic activity against OVA-expressing MCA205 fibro-
sarcoma tumor cells (Figures 2C and 2D).
To determine whether the Th17 cell capacity to blunt CD8+ T
response was specifically due to ectonucleotidase expression,
we tested the immunosuppressive effect of Th17 cells generated
from CD39-deficient mice on OT-I cell IFN-g production. We
observed that CD39-deficient (Entpd1/) Th17 cells, despite
their conserved ability to differentiate into Th17 cells (Fig-
ure S2B), had marginal capacity to blunt IFN-g production from
OT-I cells (Figure 2E, left) and decreased ability to blunt OT-I
cytotoxic activity against OVA-expressing MCA205 fibrosar-
coma tumor cells (Figure 2D), confirming the involvement of
ectonucleotidases in the immune suppression caused by Th17
cells. In addition, Adenosine 2B Receptor inhibitor but not Aden-
osine 2A Receptor inhibitor could restore IFN-g production from
OT-I cells when cultured with wild-type Th17 cells (Figure 2E,
right). As a control, we observed that both inhibitors did not
directlymodify OT-I and Th17 cell secretory or proliferation prop-
erties (Figure S2C).
Th17 cells could also affect CD4+ T cell function and demon-
strated capability to blunt IFN-g and IL-2 production from OT-II
cells in a dose-dependent manner (Figure 2F). We further found
that Th17 cells prevented release of IFN-g, TNF-a, as well as Th2
cell cytokines like IL-4 or IL-5 from purified naive CD4+ T cells
stimulated with CD3 and CD28 antibodies (Figures S2D and
S2E). Importantly, Th17 cells did not induce effector T cell death
upon coculture, thus suggesting that reduction of T cell function
is not due to direct cytotoxicity of Th17 cells on effector T cells
(Figure S2F).
Th17 cells produce IL-10, which may restrain Th1 and CD8+
T cell function (McGeachy et al., 2007). In addition, IL-17a was
proposed to affect the transcriptional program of Th1 and
CD8+ T cells (O’Connor et al., 2009). Thus, we tested the putative
role of IL-10 and IL-17a in mediating the immunosuppressive
effect of Th17 cells on OT-I T cells. Although we found IL-17a
and IL-10 secretion from Th17 cells, the addition of an IL-17a
or an IL-10 antibody did not abrogate Th17 cell capacity to
suppress IFN-g production by OT-I cells, ruling out a role for
these cytokines in the inhibition of effector T cell functions by
Th17 cells (Figure S2G).
Taken together, these results indicate that ectonucleotidase-
expressing Th17 cells generated from naive T cells in the pres-
ence of IL-6 and TGF-b have the capacity to impair effector
T cell functions.
The Transcription Factor Stat3 Directly Promotes
Ectonucleotidase Expression in Th17 Cells
Stat3 and Rorgt are the twomain transcription factors involved in
Th17 cell differentiation. Bioinformatic analysis of 4000 bp of the
promoter and the first intron of CD39 (Entpd1) and CD73 (Nt5e)
murine gene by MatInspector software identified no putativebinding site for Rorgt but one putative binding site for Stat3
(Stat3BS) located at 2785 and 3225 bp upstream of the tran-
scription initiation site of Entpd1 and Nt5e genes, respectively,
similar to the consensus sequence and conserved within mouse
and human (Figure S3A). The binding of Stat3 on the Entpd1 and
Nt5e promoters was detected in Th17 cells but not Th0 cells
(Figures 3A and 3B). To test whether Stat3 directly activates
ectonucleotidase expression, we cloned two fragments of the
Entpd1 and Nt5e promoters (of 3120 bp and 3540 bp), respec-
tively, into pGl3-basic luciferase reporter plasmid. The activity
of the two promoters was significantly enhanced in NIH 3T3 cells
cotransfected with a constitutively active Stat3 mutant, Stat3C
(Figure 3C). To validate the involvement of Stat3 in ectonucleoti-
dase expression, we demonstrate that STA21, a specific inhib-
itor of Stat3 dimerization or the silencing of Stat3 with specific
siRNA abolish the Entpd1 and Nt5e promoter activities induced
by STAT3C (Figure 3D).
We further confirmed the involvement of Stat3 in ectonucleo-
tidase expression in CD4+ T cells differentiated with TGF-b plus
IL-6, where we found that both STA21 and lentivirus encoding
a specifically designed Stat3 siRNA decreased the expression
of CD39 and CD73 both at the mRNA and the protein level
(Figures 3E and S3B). As control, CD4+ T cells differentiated
with TGF-b plus IL-6 in the presence of STA21 did not express
Foxp3 (Figure S3B). Finally CD4+ T cells differentiated with
TGF-b plus IL-6 generated in the presence of STA21 had
decreased ability to generate adenosine from ADP (Figure 3F)
and were unable to abrogate IFN-g production by OT-I cells (Fig-
ure 3G). Altogether these data demonstrate that ectonucleoti-
dases are induced in Th17 cells through Stat3.
TGF-b Regulates Ectonucleotidase Expression through
Downregulation of the Transcriptional Repressor Gfi-1
TGF-b was shown to downregulate the expression of the tran-
scriptional repressor Gfi1, a gene induced by TCR triggering
(Zhu et al., 2002, 2009). Because bioinformatic analysis of ecto-
nuclease promoters revealed one putative binding site of Gfi-1
(Gfi-1BS) at 1500 and 2059 bp upstream of the transcription
initiation site of CD39 and CD73, respectively, we hypothesized
that this transcription factor might prevent ectonucleotidase
expression in Th17 cells (Figure S3A). To test this, we performed
chromatin immunoprecipitation to analyze interactions between
Gfi-1 and the GfiBS identified in the Entpd1 and the Nt5e
promoters. We found that Gfi-1 binds to its predicted binding
site in the Entpd1 and the Nt5e promoters in naive T cells acti-
vated with anti-CD3 and anti-CD28 in the absence of differenti-
ating cytokines (Th0) or with IL-6 alone. However, interaction
between Gfi-1 and the Entpd1 and the Nt5e promoters was
barely detectable in Th17 cells differentiated in the presence of
IL-6 plus TGF-b (Figure 4A). To test whether Gfi-1 could repress
ectonucleotidase expression, we repeated reporter luciferase
assays. Because STAT3C directly activated Entpd1 and Nt5e
promoter transactivation in NIH 3T3 cells (Figure 3C), we hypoth-
esized that NIH 3T3 cells do not constitutively express Gfi-1. Via
immunoblotting, we indeed observed that NIH 3T3 cells did not
express Gfi-1 (Figure S4A). As expected, STAT3C-dependent
Entpd1 and Nt5e promoter transactivation in 3T3 cells was in-
hibited by cotransfection of Gfi-1 (Figure 4B), thus suggesting
that Gfi-1 directly suppressed Stat3-mediated transcription ofImmunity 36, 362–373, March 23, 2012 ª2012 Elsevier Inc. 365
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Figure 3. Stat3 Enhances Ectonucleotidase Expression in Th17 Cells
(A and B) ChIP analysis of the interaction of Stat3 to the Entpd1 (A) and the Nt5e (B) promoters in in vitro differentiated Th0 or control Th17 cells.
(C) Transactivation of the Entpd1 orNte5 promoters by Stat3. Reporter constructs for the Entpd1 orNte5 promoters were cotransfected in 3T3 cells with a vector
coding for a constitutively active form of Stat3, and the firefly luciferase activity was determined 48 hr later and normalized to the renilla luciferase activity of
a cotransfected control.
(D) Same as in (C) in the presence of STA21 or Stat3 siRNA.
(E) Th17 cells were generated from naive T cells with TGF-b and IL-6 in the presence of STA21, lentivirus encoding a specifically designed control siRNA or Stat-3
siRNA, and the expression of CD39 and CD73 was analyzed by flow cytometry at 96 hr.
(F) Th17 cells were induced as in (E) and their ability to hydrolyze extracellular 14C-radiolabeled ADP to adenosine was determined.
(G) Th17 cells were as in (E) and were subsequently cocultured with TCR transgenic CD8+ OT-I cells together with the OVA-derived SIINFEKL peptide for 72 hr.
IFN-g levels were then assessed by ELISA.
Representative data from one of three experiments are shown. For two-group comparisons, the Mann-Whitney rank sum test was used (A–D, F, G). For multiple
groups comparison, the Kruskal-Wallis statistics test followed by Dunn’s post test was used (E). Graphs show mean ± SEM, *p < 0.05.
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Figure 4. Gfi-1 Represses Ectonucleotidases Expression in Th17 Cells
(A) ChIP analysis of the interaction of Gfi-1 to the Entpd1 and the Nt5e promoters in in vitro differentiated CD4 T cells with TGF-b and IL-6 or IL-6 alone or without
cytokine as control (Th0).
(B) Gfi-1 inhibits the transactivation of the Entpd1 or Nte5 promoters by Stat3. Reporter constructs for the Entpd1 or Nte5 promoters were cotransfected in 3T3
cells with a vector coding for a constitutively active form of Stat3 in the absence or presence of a Gfi-overexpression vector, and the firefly luciferase activity was
determined 48 hr later and normalized to the renilla luciferase activity of a cotransfected control.
(C) Naive CD4+ T cells from Rorgt reporter mice were differentiated into Th17 cells with TGF-b and IL-6, IL-1b, IL-6 and IL-23 (iTh17), or TGF-b, IL-1b, IL-6, and
IL-23 (iTh17+TGF-b) for 72 hr. The expression of CD39 and CD73 on Rorgt-expressing cells is depicted.
(D) Th17 cells were differentiated as in (C) and the expression of Entpd1 (left), Nt5e (middle), and Gfi1 (right) at 72 hr after activation was assessed by RT-PCR.
(E) Th17 cells were as in (C) and were subsequently cocultured with TCR transgenic CD8+ OT-I cells together with the OVA-derived SIINFEKL peptide for 72 hr.
IFN-g concentrations were then assessed by ELISA.
Representative data from one of three (A, B) or two (C–E) experiments are shown. For multiple groups comparison, the Kruskal-Wallis statistics test followed by
Dunn’s post test was used (A, B, D, E). Graphs show mean ± SEM, *p < 0.05.
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CD39 or in CD73 promoter, suggesting that the TGF-b-driven
Foxp3 expression is not sufficient to induce ectonucleotidases.
In addition, we have generated IL-9-producing CD4+ T (Th9) cells
(Dardalhon et al., 2008) in the presence of TGF-b and IL-4 and
monitored the expression of ectonucleotidases. We observed
that Treg and Th17 cells expressed ectonucleotidases in
contrast to Th9 cells (Figure S4B) thus suggesting that ectonu-
cleotidases expression is not solely due to TGF-b signaling.
The higher Gfi-1 expression in Th9 cells compared to Treg and
Th17 cells may explain the absence of ectonucleotidase expres-
sion in Th9 cells (Figure S4B).
Although initial reports have proposed that TGF-b and IL-6
were both required for the induction of Th17 cells from naive
T cells, recent studies have suggested that TGF-bwas not indis-pensable for Th17 cell development (Das et al., 2009; Ghoreschi
et al., 2010). Interestingly, Th17 cells generated with IL-1b, IL-6,
and IL-23 but without TGF-b were highly pathogenic in the
mouse model of multiple sclerosis (and called here iTh17 cells
for inflammatory Th17 cells), whereas Th17 cells generated
with TGF-b and IL-6 failed to trigger significant autoimmunity
signs in vivo (Ghoreschi et al., 2010). Because TGF-b represses
Gfi-1 expression, we hypothesized that, in contrast to Th17 cells,
iTh17 cells would not express ectonucleotidases. To verify this,
we tested ectonucleotidases expression on Th17, iTh17, and
TGF-b-treated iTh17 cells. Although all three Th17 cell subsets
expressed Rorgt and produced IL-17 (Figure S4C), the presence
of TGF-b was necessary to negatively regulate Gfi1 expression
and was required for CD39 and CD73 ectonucleotidase expres-
sion (Figure 4D). Accordingly, only Th17 cells generated withImmunity 36, 362–373, March 23, 2012 ª2012 Elsevier Inc. 367
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ability to abrogate IFN-g secretion from activated OT-I CD8
T cells (Figure 4E). Therefore, the downregulation of Gfi1 by
TGF-b during Th17 cell differentiation enables the expression
of ectonucleotidases and accounts for the immunosuppressive
functions of Th17 cells.
Respective Role of IL-6 and TGF-b in Ectonucleotidase
Expression
To determine the respective role of IL-6 and TGF-b in ectonu-
cleotidase expression, we have performed a dose effect of
IL-6 and TGF-b. We have noted that at fixed dose of IL-6
(20 ng/ml), at least 1 ng/ml of TGF-b was required to induce
expression of Entpd1 and Nt5e (Figures 5A and 5B). We noted
that Gfi1 expression significantly decreased below Th0 cell
levels at the dose of 1 ng/ml of TGF-b, which is in line with our
hypothesis that Gfi-1 negatively regulates ectonucleotidase
expression in Th17 cells (Figure 5C). In this context of increasing
dosage of TGF-b, we observed a statistically significant correla-
tion between Entpd1 and Nt5e expression and a negative corre-
lation between Gfi1 expression and expression of Entpd1 and
Nt5e, thus corroborating the role of TGF-b in the regulation of
Gfi1 and ectonucleotidase expression (Figure 5D).
Upon testing the addition of increasing doses of IL-6 with
a fixed dose of TGF-b (2 ng/ml), we also observed that high
doses of IL-6 enhanced ectonucleotidase expression in Th17
cells (Figures 5E and 5F). Increasing doses of IL-6 did not affect
Gfi1 expression (Figure 5G). In this context, we also observed
a correlation between Entpd1 andNt5e expression but no corre-
lation between Gfi1 expression and expression of Entpd1 and
Nt5e (Figure S5), thus corroborating that IL-6 is important for
ectonucleotidase transcriptional expression but not through
Gfi-1 regulation.
TGF-b can signal through Smad-dependent and Smad-inde-
pendent pathways. Smad-independent TGF-b signaling occurs
through various pathways including the Ras-extracellular
signal-regulated kinase (Erk), TGF-b-activated kinase-mitogen-
activated protein kinase (MAPK) kinase 4-c-Jun N-terminal
kinase (TAKMKK4- JNK), TAK-MKK3/6-p38, Rho-Rac-cdc42
MAPK, and phosphatidylinositol 3-kinase (PI3K)-Akt pathways
(Derynck and Zhang, 2003). To determine the molecular mecha-
nism of Gfi-1 regulation by TGF-b, we examined the effect of
inhibitors for these pathways on Gfi1 expression and observed
that only the inhibitor of TGF-b1 activin receptor-like kinase
(ALK) receptors and the p38 inhibitors regulated Gfi-1 expres-
sion, suggesting that the downregulation of Gfi1 expression by
TGF-b is driven in a Smad-independent manner through p38
activation. Accordingly, Entpd1 and Nt5e ectonucleotidase
expression is also downregulated only through p38 inhibition
but not Smad inhibition (Figure 5H).
Tumor-Infiltrating Th17 Cells Express
Ectonucleotidases In Vivo and Suppress Anticancer
Immune Responses
Because our in vitro data indicated that the immunosuppressive
activity of Th17 cells was dependent on their expression of ecto-
nucleotidases, we examined the in vivo relevance of this obser-
vation in mouse cancer models, where the presence of TGF-b in
the tumor microenvironment has been shown to contribute to368 Immunity 36, 362–373, March 23, 2012 ª2012 Elsevier Inc.tumor progression (Nakamura et al., 2001). We examined the
phenotype of tumor-infiltrating Th17 cells in EL4 thymoma,
B16F10 melanoma, LLC lung carcinoma, and MC38 colon carci-
noma tumors. With Rorgt-EGFP transgenic mice, we found that
intratumor Rorgt-expressing CD4+ T cells expressed both CD39
and CD73 (Figures 6A and 6B). Moreover, adoptive transfer of
Th17 cells reduced the antitumor effect of adoptively transferred
OT-I cells in the MCA205OVAmodel of lung metastasis whereas
Entpd1-deficient Th17 cells failed to do so (Figure 6C). Similarly,
the adoptive transfer of wild-type Th17 cells but not wild-type
Th0 or Entpd1-deficient Th17 cells enhanced the growth of
EL4 tumors (Figure 6D). The adoptive transfer of wild-type
Th17 cells had no protumor effect in nude mice, indicating that
the transfer of Th17 cells mainly acted on T cell-dependent
immunity. Additionally, wild-type Th17 cell transfer reduced
Tbx21 (coding for T-bet) expression in CD3+ tumor-infiltrating
lymphocytes (Figure 6E). Collectively, these results illustrate
the ability of Th17 cells to promote tumor growth through their
expression of ectonucleotidases that impair antitumor T cell
responses.
DISCUSSION
In this study, we showed that the CD39 and CD73 ectonucleoti-
dases control Th17 cell capacity to regulate CD4+ and CD8+
T cell effector functions. We found that the IL-6-Stat3 and
TGF-b-Gfi-1 pathways were both required to induce ectonucleo-
tidases in Th17 cells. Tumor-infiltrating Th17 cells expressed
ectonucleotidases and adoptive transfer of Th17 cells promoted
tumor growth in a CD39-dependent manner, thus demonstrating
that ectonucleotidase expression supports Th17 cell immuno-
suppressive functions in cancer.
The proinflammatory and pathogenic function of Th17 cells
have been illustrated in mouse models of autoimmune diseases
and in humans (Stockinger et al., 2007; Tesmer et al., 2008; Zhou
and Littman, 2009). It has, however, been suggested that the
stimulation of effector T cells with TGF-b and IL-6 abrogated their
pathogenic function despite upregulation of IL-17 production
(McGeachy et al., 2007). In addition, it was shown that IL-17A
and IL-17F do not mediate autoimmune inflammation in mice,
suggesting that the effector properties of Th17 cells are not
primarily determined by IL-17 production (Haak et al., 2009). In
line with these studies, we found that Th17 cells differentiated
with TGF-b and IL-6 exhibited regulatory properties against
effector T cells that were independent of IL-17 but required the
expression of CD39 and CD73. The generation of Th17 cells
from naive T cells activated with IL-1b, IL-6, and IL-23 in the
absence of TGF-b has been reported (Ghoreschi et al., 2010).
These Th17 cells induced without TGF-bwere highly pathogenic
in vivo unlike Th17 cells generated with TGF-b and IL-6 (Ghore-
schi et al., 2010). Notably, we have shown that Th17 cells differ-
entiated without TGF-b failed to express ectonucleotidases,
suggesting that ectonucleotidase expression actually deter-
mines the effector immunoregulatory fate of Th17 cells.
TGF-b is a major immunoregulatory cytokine that has been
shown to favor cancer progression in humans (Bierie andMoses,
2010; Korpal and Kang, 2010). The high amounts of TGF-b in the
tumor microenvironment promote the survival of cancer cells
through the induction of Foxp3+ regulatory T cells and the
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Figure 5. The Role of IL-6 and TGF-b in Ectonucleotidase Expression
Naive T cells were stimulated 3 days with anti-CD3, anti-CD28 with IL-6 (20 ng/ml), and increasing doses of TGF-b.
(A–C) Quantitative real-time PCR (RT-PCR) relative to the expression of mRNA encoding cyclophilin to examine expression of Entpd1 (A),Nt5e (B), andGfi1 (C) at
72 hr after activation.
(D) Correlation between Entpd1 andGfi1 expression, Nt5e andGfi1 expression, and Entpd1 and Nt5e expression. Naive T cells were stimulated 3 days with anti-
CD3, anti-CD28 with TGF-b (2 ng/ml), and increasing doses of IL-6.
(E–G) Quantitative real-time PCR (RT-PCR) relative to the expression of mRNA encoding cyclophilin to examine expression of Entpd1 (E), Nt5e (F), andGfi1 (G) at
72 hr after activation.
(H) Expression of Entpd1, Nt5e, and Gfi1 mRNAs was determined by real-time PCR in naive T cells treated with chemical inhibitors. Naive T cells were cultured
with anti-CD3, anti-CD28, and with TGF-b and IL-6 either alone or supplemented with the Smad3 inhibitor (SIS3), TGF-b receptor kinase inhibitor (SB431542), the
p38 inhibitor (SB203580), the JNK inhibitor (SP600125), the PI3 kinase inhibitor (LY294002), and the ROCK inhibitor (Y27632) for 72 hr, and total RNA was then
isolated. The relative expression of Entpd1, Nt5e, and Gfi-1 mRNA were normalized to Cyclophilin.
For multiple group comparison, the Kruskal-Wallis statistics test followed by Dunn’s post test was used (A–C, E–H). Graphs show mean ± SEM, *p < 0.05.
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Figure 6. Ectonucleotidase Expression on Th17 Cells Regulates Their Immunosuppressive Function In Vivo
Rorgt-EGFP reporter mice were inoculated with 106 EL4 thymoma, B16F10 melanoma, LLC1 lung adenocarcinoma, or MC38 colon carcinoma cancer cells s.c.
Upon reaching 150–200 mm2, tumors were excised and the expression of CD39 and CD73 was analyzed by flow cytometry on CD4+ lymphocytes.
(A) Representative flow cytometry analysis of ectonucleotidase expression on Rorgt-expressing CD4 cells from EL4 tumor-bearing mice.
(B) The expression of ectonucleotidase is depicted on Rorgt-expressing CD4 cells from tumor-bearing mice.
(C) 33 105 MCA205OVA fibrosarcoma cells were injected i.v. into C57BL/6 Rag2/ mice. After 24 hr, mice received 23 106 OT-I cells along with 23 106 Th17
cells from Entpd1+/+ and Entpd1/ hosts. The number of lung metastases was determined after 11 days.
(D) Wild-type or nude C57BL/6 mice were injected s.c. with 106 EL4 thymoma cancer cells along with 23 106 Th17 cells generated in vitro with TGF-b and IL-6
from Entpd1+/+ or Entpd1/ mice or with Th0 cells i.v. Tumor growth was monitored biweekly.
(E) Wild-type C57BL/6mice were injected s.c. with 106 EL4 thymoma cancer cells alone (Control) or with 23 106 Th17 cells generated in vitro with TGF-b and IL-6
or with Th0 cells i.v. CD3+ tumor infiltrating T lymphocytes were isolated 15 days after injection of tumor cells. tbx21mRNA expression was determined by real-
time PCR. The relative expression of tbx21 mRNA was normalized to Cyclophilin.
For multiple groups comparison, the Kruskal-Wallis statistics test followed by Dunn ’s post test was used (C, E). Graphs show mean ± SEM, *p < 0.05.
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responses (Ghiringhelli et al., 2005a, 2005b). Our study here
suggests that by driving ectonucleotidase expression on Th17
cells, TGF-b also contributes to the inhibition of anticancer
immunity. In four different transplantable tumor models, we
have noted that tumor-infiltrating Th17 cells harbored ectonu-
cleotidases, suggesting that ectonucleotidase expression by
Th17 cells in the tumor microenvironment might be a general
feature associated with cancer. It has recently been proposed
that soluble nucleotidases could directly stimulate tumor cell
proliferation and limit cell death triggered by extracellular ATP370 Immunity 36, 362–373, March 23, 2012 ª2012 Elsevier Inc.(Feng et al., 2011). However, although our data clearly indicate
that CD39+CD73+ Th17 cells inhibit T cell effector functions,
ectonucleotidase-expressing Th17 cells failed to promote the
growth of tumors implanted into Nudemice upon adoptive trans-
fer, suggesting that the regulatory activity of CD39+CD73+ Th17
cells is primarily mediated through the regulation of T cell-based
immune responses.
Although Th17 cells are characterized by their expression of
Rorgt and their secretion of proinflammatory mediators such
as IL-17, it is noteworthy that the pathogenicity of mouse Th17
cells generated in vitro from naive CD4+ T cells is highly
Immunity
Ectonucleotidase Expression by Th17 Cellsdependent on the experimental conditions used for differentia-
tion. It is notable that even in the presence of IL-23 along with
TGF-b and IL-6, Th17 cells obtained after a first round of stimu-
lation were poorly pathogenic whereas Th17 cells that had been
restimulated in vitro in the presence of anti-CD3 and anti-CD28
without any differentiating cytokines were highly pathogenic
(Ja¨ger et al., 2009). In addition, Th17 cells generated in the
absence of TGF-b also show highly pathogenic behavior in
comparison to Th17 cells induced with TGF-b and IL-6 (Ghore-
schi et al., 2010). Thus, our work indicating that the expression
of ectonucleotidases dictates that the proinflammatory proper-
ties of Th17 cells might reconcile these apparently contradictory
findings and suggests that the proinflammatory functions of
Th17 cells are mainly driven by their expression of ectonucleoti-
dases. Our preliminary observations indeed indicate that after
a second restimulation in the absence of TGF-b, Th17 cells
lose ectonucleotidase expression and their immunosuppressive
behavior. We propose that TGF-b, by repressing the transcrip-
tional repressor Gfi-1 that blocks ectonucleotidase expression,
acts as a molecular switch that actually confers regulatory prop-
erties to Th17 cells in cancer. A study from Waldmann’s group
corroborates that TGF-b regulates CD73, and to a lesser extent
CD39, expression in both CD8 and CD4 T cells (Regateiro et al.,
2011). However, they did not observe any effect of IL-6 on ecto-
nucleotidase expression. This discrepancy may rely in the use
of a bulk CD4 T cell population, which contains CD39-expressing
memory T cells.
Stat3 expression is required for ectonucleotidase expression.
Interestingly, although both Treg and Th17 cells expressed
pStat3, Stat3 inhibition in both Treg and Th17 cells blunted ecto-
nucleotidase expression, underscoring a close relationship
between Th17 cells and Treg cells.
In conclusion, we found that Stat3 and Gfi-1 are essential
regulators of ectonucleotidase expression during Th17 cell
differentiation. Th17 cells expressing ectonucleotidases inhibit
effector T cell functions, resulting in depressed anticancer immu-
nity. By uncovering the transcriptional regulation of ectonucleo-
tidase expression, our results provide molecular targets that
might be therapeutically exploited for cancer treatment.EXPERIMENTAL PROCEDURES
Mouse Strains
All animals were bred and maintained according to both the FELASA and the
Animal Experimental Ethics Committee Guidelines (University of Burgundy,
France). Animals were used at between 6 and 20 weeks of age. C57BL/6
Rag2/ and C57BL/6 CD45.1 mice were purchased from the cryopreserva-
tion, Distribution, Typage et Archivage animal (Orle´ans, France). OT-I and
OT-II mice were gifts from C. Borg (Besanc¸on, France), Entpd1/ were
from S.C.R., Ifng/ mice were from B.R., and Rorgt-eGFP reporter mice
were from G.E. and have been previously described (Eberl et al., 2004).
Tumor Cell Lines and Transplantable Tumors
EL4 thymoma cells, EG7 cells (OVA-transfected EL4 cells), B16F10 melanoma
cancer cells, MC38 colon cancer cells, MCA205 fibrosarcoma cells, and LLC
lung cancer cells (all syngenic from C57BL/6 mice) were cultured at 37C
under 5% CO2 in RPMI with 10% (vol/vol) Fetal Calf Serum supplemented
with sodium pyruvate, penicillin and streptomycin, and 10 mM HEPES. To
induce tumor formation, 106 cancer cells were injected s.c. into C57BL/6
mice. All experiments were carried out in accordance with guidelines
prescribed by the Ethics Committee at the University of Burgundy.In Vitro T Cell Differentiation
Naive CD4+ T cells (CD4+CD62Lhi) were obtained from spleens and lymph
nodes of C57BL/6 wild-type. Cells were then purified by flow cytometry (BD
ARIA III with FACSDiva Software) accordingly. The purity of isolated T cell
populations routinely exceeded 95%. Naive T cells were stimulated with
plate-bound antibodies against CD3 (145-2C11, 2 mg/ml) and CD28 (PV-1,
2 mg/ml) in the presence of either no cytokines (Th0); IL-12 (Th1); IL-4 (Th2);
TGF-b (Treg); IL-1b, IL-6, and IL-23 (Th1723); TGF-b and IL-6 (bTh17); and
TGF-b and IL-4 (Th9). Mouse IL-1b (20 ng/ml), IL-4 (20 ng/ml), IL-6
(20 ng/ml), IL-12 (10 ng/ml), IL-23 (25 ng/ml), and TGF-b (2 ng/ml) were all
purchased from R&D Systems. IL-4 (clone 1B11) and IL-12 (clone C17.8)
(10 mg/ml) antibodies were obtained from BioXcell (West Lebanon, NH,
USA). The Stat3 inhibitor, STA21, A2a, and A2b inhibitors were purchased
from Sigma-Aldrich and added at the start of the cultures at a final concentra-
tion of 30 mM.
siRNA
siRNA knockdown experiments were performed with validated control or
Stat3-specific siRNAs according to the manufacturer’s instructions (Invitro-
gen). In brief, naive CD4+ T cells were differentiated into Th17 cells by activa-
tion with anti-CD3, anti-CD28, TGF-b (2 ng/ml), and IL-6 (20 ng/ml) with T cell
differentiation medium in the presence of siRNA at a final concentration of
10 nM.
For T cells transfection, the siRNA was designed to target the sequences
50-GAGTCACATGCCACGTTGG-30 of mouse Stat3. The sense (50-AAAGGAG
TCACATGCCACGTTGG-30) and antisense (50-AAAACCAACGTGGCATGTGA
CTC-30) sequences were annealed and cloned into the BbsI site of the 30
LTR of pFIV-H1/U6 vector according to manufacturer’s instructions (System
Biosciences). Scrambled siRNA were included as control. Recombinant
viruses were produced by transient transfection into 293T cells by pFIV-
PACK Lentiviral packaging kit (System Biosciences). Infectious lentiviruses
were collected after 36–48 hr. Transductions of T cells were performed
on 48-well plates with the addition of 5 mg/ml Polybrene (Sigma-Aldrich).
The cells were exposed to lentiviral concentrates at a concentration of
5 3 105 cells/ml.
ATPase and ADPase Assays
T cells were washed three times in cold phosphate-free buffer. Cells were
warmed in incubation buffer (10 mM glucose, 20 mM HEPES (pH 7.5), 5 mM
KCl, 120 mM NaCl, 2 mM CaCl2, and 5 mM tetramisole) to 37
C for 10 min.
Cells were then incubated in the same buffer with 2 mM ATP for 10 min. Reac-
tions were stopped with the addition of trichloroacetic acid to a final concen-
tration of 5% and immediately put on ice. Phosphate concentration was
measured after the addition of Malachite green/polyvinyl alcohol/ammonium
molybdate solution for 20 min by a spectrophotometer (ELx808 Ultra Micro-
plate Reader; Bio-Tek Instruments, Inc.) at 610 nm and compared against
a standard curve.
Measurement of ATP Degradation by CD4 T Cell Subsets by TLC
2 mCi/ml [14C]ADP (Ge Healthcare) was added to cell cultures; aliquots were
removed and analyzed for the presence of [14C]ADP hydrolysis products by
TLC (three different cell culture preparations).
Measurement of Cytokines
Secreted cytokines were measured after 72 hr by ELISA (BD Biosciences). For
intracellular cytokine staining, cells were cultured as described above and then
stimulated for 4 hr at 37C in culture medium containing PMA (50 ng/ml;
Sigma), ionomycin (1 mg/ml; Sigma), and monensin (GolgiStop; 1 ml/ml; BD
Biosciences). After staining for surface markers, cells were fixed and permea-
bilized according to the manufacturer’s instructions (BD Biosciences), then
stained for intracellular products.
Flow Cytometry
We used antibodies directed against mouse CD3, CD4, IFN-g, granzyme B,
CD39, and CD73 all purchased from BD Biosciences. All acquisitions were
performed with a BD LSR-II cytometer equipped with BD FACSDiva software,
and all data were analyzed with FlowJo software (Tree Star, Ashland, OR).Immunity 36, 362–373, March 23, 2012 ª2012 Elsevier Inc. 371
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We used the Smad3 inhibitor (SIS3), TGF-b receptor kinase inhibitor
(SB431542), the p38 inhibitor (SB203580), the JNK inhibitor (SP600125), the
PI3 kinase inhibitor (LY294002), and the ROCK inhibitor (Y27632). All were
obtained from Merck Chemical France.
Quantitative PCR Analysis
Total RNA from T cells was extracted with Trizol (Invitrogen). 100 to 300 ng of
RNA was reverse-transcribed into cDNA by M-MLV reverse transcriptase,
Random Primers, and RNaseOUT inhibitor (Invitrogen). cDNA were quantified
by real-time PCR with a SYBR Green Real-time PCR kit (Applied Biosystems)
on a Fast7500 detection system (Applied Biosystems, France). Relative mRNA
levels were determined with the DCt method. Values were expressed relative
to cyclophilin A. The sequences of the oligonucleotides used are described in
Table S1.
Chromatin Immunoprecipitation Assay
Chromatin immunoprecipitation (ChIP) assay was performed with the ChIP-IT
kit (Active Motif Europe, Rixensart, Belgium) according to the manufacturer’s
instructions. In brief, 53 106 cells were fixed with 1% formaldehyde to cross-
link DNA with proteins, lysed, and passed through a 26 gauge-needle to aid in
nuclei release. After enzymatic digestion, DNA was immunoprecipitated with
3 mg of Stat3 or Gfi-1 antibodies (Santa Cruz), or 3 mg of negative control immu-
noglobulin G (IgG) at 4C overnight. After addition of protein G beads, the
protein G/Antibody/Chromatin mixture was washed and eluted from the
protein G with supplied buffers. Then, cross-link was reversed and samples
were analyzed by quantitative PCR. The sequences of the oligonucleotides
used are described in Table S1.
Plasmid Constructs
The pCD39 and pCD73 luciferase constructs were obtained by inserting
3120 bp and 3335 bp fragments of mouse CD39 and CD73 gene promoter,
respectively, in the multicloning site of the pGl3 basic vector (Promega, Char-
boniere, France). Fragments were amplified by high-fidelity PCR via human
genomic DNA as template and specific primers. The sequences of the oligonu-
cleotides used are described in Table S1. Stat3C and GFI-1 plasmid were
given by C. Borg (Besancon, France) and J. Zhu (Bethesda, MD, USA),
respectively.
Transient Transfections and Luciferase Transactivation Assays
HumanNIH/3T3 cells (cultured in DMEM4.5 g/l + glutamine + FBS at 37C, 5%
CO2) were transiently transfected for 48 hr with reporter plasmids with lipofect-
amine 2000 (Invitrogen). Luciferase was measured with the Dual Glo Lucif-
erase Assay System (Promega) according to the manufacturer’s instructions.
In brief, Dual Glo Luciferase Reagent was added to the cells. After 10 min incu-
bation, firefly luciferase wasmeasured with aWallac 1440 Victor2 luminometer
(PerkinElmer, Courtaboeuf, France). The reaction was stopped with Dual-Glo
Stop and Glo Reagent for 10 min and the renilla luciferase was then measured.
Statistical Analysis
Statistical analysis was performed with Prism software (Graph Pad software,
La Jolla, CA). p values < 0.05 were considered significant. For two-group
comparisons, the Mann-Whitney rank sum test or the Wilcoxon signed-rank
test was used. For multiple groups comparison, the Kruskal-Wallis statistics
test followed by Dunn’s post test was used.
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